Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
Year: 2022
Type: article
Source: Blood
Authors: Jonathan W. Friedberg, Carrie A. Thompson, Marek Trněný, Franck Morschhauser, Gilles Salles, Patrick M. Reagan, Mark Hertzberg, Piotr Smolewski, Huilai Zhang, Catherine Thieblemont, Bei Hu, Gustavo Fonseca, Won-Seog Kim, Maurizio Martelli, Amitkumar Mehta, Avrita Campinha-Bacote, Mark Yan, Jamie Hirata, Matthew Sugidono, Calvin Lee, Jeff P. Sharman
Institutions: University of Rochester Medicine, University of Rochester, Mayo Clinic, Charles University, Université de Lille, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Memorial Sloan Kettering Cancer Center, Prince of Wales Hospital, Medical University of Lodz, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Levine Cancer Institute, Sungkyunkwan University, Sapienza University of Rome, University of Alabama at Birmingham, Annexon Biosciences (United States), Roche (Canada), Willamette Valley Cancer Institute and Research Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310107958